Abstract
We previously conducted a randomized double-blinded clinical cohort study on topical tacrolimus safety issues in 1–3-year-old children with atopic dermatitis. Five years on, the participants were contacted via a postal questionnaire to obtain long-term data. There were no significant differences regarding infections, growth parameters (height, weight, body mass index), quality of life and disease severity between use of topical tacrolimus and topical corticosteroids.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
